Document Detail


Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients.
MedLine Citation:
PMID:  18191989     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To investigate subclinical atherosclerosis and the effect of treatment in patients with early rheumatoid arthritis (RA). PATIENTS AND METHODS: Forty patients with early RA who met the revised American College of Rheumatology (ACR) criteria and disease duration of <1 year were included in the study. Smokers and patients with classical risk factors for atherosclerosis were excluded. The serum levels of total cholesterol (TC), triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol were determined in all patients before and after 1 year of therapy. Carotid artery intima-media thickness (IMT) and carotid plaque were measured before and after treatment. RA disease activity was measured using the 28 joint indices score (DAS-28) and clinical improvement was determined by the ACR response criteria. Forty-five age- and sex-matched nonsmoking volunteers were used as controls. All patients were treated with methotrexate and prednisone. RESULTS: RA patients had a baseline mild dyslipidemia characterized by a decrease in serum HDL-C levels and a high TC/HDL-C atherogenic ratio compared with controls. Both lipid parameters were significantly improved after treatment (P<0.01). Common carotid artery IMTs at baseline were higher in RA patients compared with controls (P<0.05). After 1 year of therapy there was a significant decrease in the IMTs (P<0.001). Thirty-five patients (88%) achieved the ACR 20%, while 30 (75%) reached the ACR 50% response criteria. A significant decrease of DAS-28 was observed after treatment (P<0.03). CONCLUSIONS: The atherogenic lipid profile and subclinical atherosclerosis are features of early RA, which improved after therapy. Early intervention and control of the disease activity may reduce the risk of atherosclerosis and cardiovascular events in patients with RA.
Authors:
Athanasios N Georgiadis; Paraskevi V Voulgari; Maria I Argyropoulou; Yannis Alamanos; Moses Elisaf; Alexandros D Tselepis; Alexandros A Drosos
Related Documents :
1906939 - Intestinal mucosal permeability in inflammatory rheumatic diseases. ii. role of disease.
15124939 - Hla-drb1* alleles and temporomandibular joint erosion in patients with various rheumati...
24487699 - Further evidence about the crucial role of csf biomarkers in diagnosis of posterior cor...
21071479 - Ultrasound doppler measurements predict success of treatment with anti-tnf-α drug in p...
11669239 - Effects of diets containing fish oil and vitamin e on rheumatoid arthritis.
6971489 - Monocyte cytotoxicity in connective tissue diseases. correlation with disease groups.
9725309 - Sonography of achilles tendon xanthomas in patients with heterozygous familial hypercho...
21207349 - Anticoagulant-associated intracerebral hemorrhage.
8727199 - The congenital dislocated spine.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-01-14
Journal Detail:
Title:  Seminars in arthritis and rheumatism     Volume:  38     ISSN:  0049-0172     ISO Abbreviation:  Semin. Arthritis Rheum.     Publication Date:  2008 Aug 
Date Detail:
Created Date:  2008-07-22     Completed Date:  2008-11-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1306053     Medline TA:  Semin Arthritis Rheum     Country:  United States    
Other Details:
Languages:  eng     Pagination:  13-9     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Arthritis, Rheumatoid / complications,  drug therapy*
Cardiovascular Diseases / complications*
Female
Humans
Immunosuppressive Agents / therapeutic use*
Male
Methotrexate / therapeutic use
Middle Aged
Prednisone / therapeutic use
Risk Factors
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 53-03-2/Prednisone; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Trace element concentrations in blood of harbor seals (Phoca vitulina) from the Wadden Sea.
Next Document:  Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping co...